Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXN PR for Severe Parkinson's Disease Associated Pain
NCT01439100Phase 3Completed
- Sponsor
- Mundipharma
- Start
- Oct 2011
- Primary completion
- Aug 2013
- Countries
- 7
01
Overview
A Phase 3 trial of oxycodone + naloxone in Parkinson's disease (PD), sponsored by Mundipharma. Started Oct 2011; status: completed.
02
Drugs
oxycodone + naloxone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01439100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01439100.